[M03AB01, succinylcholine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Naltrexone.]
[J01EC01, sulfamethoxazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Sulfamethoxazole.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Naltrexone.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Temazepam.]
[N05AE05, lurasidone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Apomorphine.]
[R03DA07, theobromine, The therapeutic efficacy of Theobromine can be decreased when used in combination with Naltrexone.]
[R06AD03, thiethylperazine, The risk or severity of hypotension and CNS depression can be increased when Thiethylperazine is combined with Naltrexone.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Naltrexone.]
[N05AB08, thioproperazine, The risk or severity of hypotension and CNS depression can be increased when Thioproperazine is combined with Naltrexone.]
[N05AC02, thioridazine, The risk or severity of hypotension and CNS depression can be increased when Thioridazine is combined with Naltrexone.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Naltrexone is combined with Tilidine.]
[M03BX04, tolperisone, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Naltrexone.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Naltrexone.]
[C03DB02, triamterene, The therapeutic efficacy of Triamterene can be decreased when used in combination with Naltrexone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Triazolam.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naltrexone.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Naltrexone.]
[N05AB06, trifluoperazine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Naltrexone.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Naltrexone.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Naltrexone.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Naltrexone.]
[R06AD01, trimeprazine, The risk or severity of hypotension and CNS depression can be increased when Alimemazine is combined with Naltrexone.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Naltrexone.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Naltrexone.]
[N06AA06, trimipramine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Trimipramine.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Naltrexone.]
[N06AX24, vilazodone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Naltrexone.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Naltrexone.]
[B01AC24, ticagrelor, Naltrexone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Naltrexone.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Fusidic acid.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be decreased when used in combination with Naltrexone.]
[J05AF01, zidovudine, The metabolism of Naltrexone can be increased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Naltrexone.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Naltrexone.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Ibandronate.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Ziprasidone is combined with Naltrexone.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Naltrexone.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Naltrexone.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Naltrexone.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Naltrexone.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Naltrexone.]
[A08AA11, lorcaserin, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Lorcaserin.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Naltrexone.]
[L01EX05, regorafenib, The metabolism of Naltrexone can be decreased when combined with Regorafenib.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Naltrexone.]
[J05AE04, nelfinavir, The metabolism of Naltrexone can be increased when combined with Nelfinavir.]
[N04BD02, rasagiline, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Rasagiline.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Naltrexone.]
[A03FA09, mosapride, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Donepezil.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Naltrexone.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Naltrexone.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Naltrexone.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Naltrexone.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naltrexone.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Naltrexone.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Tegaserod.]
[N02CC02, naratriptan, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Naltrexone.]
[L01EC02, dabrafenib, The metabolism of Naltrexone can be decreased when combined with Dabrafenib.]
[N06AX28, levomilnacipran, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Levomilnacipran.]
[N06AX26, vortioxetine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Vortioxetine.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Naltrexone.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Naltrexone.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Bezafibrate.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Naltrexone.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Naltrexone.]
[N05AA04, acepromazine, The risk or severity of hypotension and CNS depression can be increased when Acepromazine is combined with Naltrexone.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Naltrexone.]
[A06AH03, naloxegol, Naltrexone may increase the opioid antagonism activities of Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Naltrexone.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Naltrexone.]
[J05AP09, dasabuvir, The metabolism of Naltrexone can be decreased when combined with Dasabuvir.]
[N06AX11, mirtazapine, Naltrexone may increase the serotonergic activities of Mirtazapine.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Naltrexone.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Naltrexone is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Naltrexone.]
[N05AX15, cariprazine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Cariprazine.]
[S01EC01, acetazolamide, The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Naltrexone.]
[N05AB07, acetophenazine, The risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Naltrexone.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Acipimox.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Trabectedin.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Naltrexone.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Bromazepam.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Brompheniramine is combined with Naltrexone.]
[N06AA19, amineptin, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Amineptine.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Bumetanide.]
[N07BC01, buprenorphine, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Buprenorphine.]
[N05BE01, buspirone, The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Naltrexone.]
[N02AF01, butorphanol, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Butorphanol.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Naltrexone.]
[A06AH05, naldemedine, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Naldemedine.]
[N02BF02, pregabalin, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Pregabalin.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Naltrexone.]
[J05AE09, tipranavir, The metabolism of Naltrexone can be increased when combined with Tipranavir.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Naltrexone.]
[N04BD03, safinamide, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Safinamide.]
[L01XX59, enasidenib, The metabolism of Naltrexone can be decreased when combined with Enasidenib.]
[J05AG03, efavirenz, The metabolism of Naltrexone can be increased when combined with Efavirenz.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Naltrexone.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Brotizolam.]
[C03DA03, canrenone, The therapeutic efficacy of Canrenone can be decreased when used in combination with Naltrexone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Naltrexone.]
[N06AA15, butriptyline, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Butriptyline.]
[A10BK04, ertugliflozin, The metabolism of Naltrexone can be decreased when combined with Ertugliflozin.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Captopril.]
[N03AF01, carbamazepine, The metabolism of Naltrexone can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Naltrexone.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Naltrexone.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Naltrexone.]
[B02BX09, fostamatinib, The metabolism of Naltrexone can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Cannabidiol.]
[L01EB07, dacomitinib, The metabolism of Naltrexone can be decreased when combined with Dacomitinib.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Naltrexone.]
[M03BA02, carisoprodol, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Carisoprodol.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Naltrexone.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Naltrexone.]
[A03FA08, cinitapride, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Cinitapride.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Ciprofibrate.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Naltrexone.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Cloxazolam.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Ubidecarenone.]
[G02CX05, bremelanotide, The serum concentration of Naltrexone can be decreased when it is combined with Bremelanotide.]
[L01EX15, pexidartinib, The metabolism of Naltrexone can be decreased when combined with Pexidartinib.]
[N05AA06, cyamemazine, The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Naltrexone.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be decreased when used in combination with Naltrexone.]
[M03BX08, cyclobenzaprine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Cyclobenzaprine.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Naltrexone.]
[G04BE04, yohimbine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Yohimbine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Naltrexone.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Naltrexone.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Naltrexone.]
[G03AC09, desogestrel, The metabolism of Naltrexone can be increased when combined with Desogestrel.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Naltrexone is combined with Dezocine.]
[N02CC07, frovatriptan, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Frovatriptan.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Naltrexone is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of serotonin syndrome can be increased when Eletriptan is combined with Naltrexone.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Naltrexone is combined with Chlordiazepoxide.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Naltrexone.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Naltrexone.]
[M03BB02, chlormezanone, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Chlormezanone.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Naltrexone.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naltrexone.]
[R06AB04, chlorpheniramine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Naltrexone.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Naltrexone.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naltrexone.]
[M03BB03, chlorzoxazone, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Chlorzoxazone.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Naltrexone is combined with Ethyl loflazepate.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Etofibrate.]
[M03BA05, febarbamate, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Febarbamate.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Naltrexone.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Naltrexone.]
[N06AB04, citalopram, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Citalopram.]
[C03DA05, finerenone, The therapeutic efficacy of Finerenone can be decreased when used in combination with Naltrexone.]
[N06AX25, St. John's wort extract, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Naltrexone can be decreased when combined with Asciminib.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Naltrexone.]
[B06AX04, mitapivat, The metabolism of Naltrexone can be increased when combined with Mitapivat.]
[N06AA04, clomipramine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Naltrexone is combined with Clonidine.]
[C03BA03, clopamide, The therapeutic efficacy of Clopamide can be decreased when used in combination with Naltrexone.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Naltrexone.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Halazepam.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Naltrexone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Naltrexone.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Naltrexone.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Colchicine.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Naltrexone.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Naltrexone.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Leflunomide.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Naltrexone.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Naltrexone.]
[N02CC05, almotriptan, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Almotriptan.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Ketazolam.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Naltrexone.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Naltrexone.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Naltrexone.]
[N07BC04, lofexidine, The bioavailability of Naltrexone can be decreased when combined with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Lormetazepam.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Naltrexone.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Naltrexone.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Naltrexone.]
[R03CB02, methoxyphenamine, Methoxyphenamine may increase the analgesic activities of Naltrexone.]
[C03DA04, eplerenone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Naltrexone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Naltrexone.]
[N06AX07, minaprine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Minaprine.]
[S01XA18, cyclosporine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Naltrexone.]
[N06AG02, moclobemide, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Naltrexone.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Rosuvastatin.]
[C03XA02, conivaptan, The therapeutic efficacy of Conivaptan can be decreased when used in combination with Naltrexone.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Cytarabine.]
[M03CA01, dantrolene, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Dantrolene.]
[N07BB05, nalmefene, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Nalmefene.]
[B05XA15, potassium lactate, The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Naltrexone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Nordazepam.]
[N06AX06, nefazodone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Nefazodone.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Naltrexone.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Naltrexone is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Naltrexone.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Naltrexone.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Naltrexone is combined with Desmopressin.]
[S03BA01, dexamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Dexamethasone.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Naltrexone.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Naltrexone.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Naltrexone.]
[N06BA02, dextroamphetamine, Amphetamine may increase the analgesic activities of Naltrexone.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Naltrexone.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Naltrexone is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Paroxetine.]
[B01AC04, clopidogrel, Naltrexone can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Naltrexone is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Diazepam.]
[N06AA08, dibenzepin, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Dibenzepin.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Naltrexone.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Naltrexone.]
[N05AD05, pipamperone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Pipamperone.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Naltrexone.]
[L01EB02, erlotinib, The metabolism of Naltrexone can be decreased when combined with Erlotinib.]
[C03CA03, piretanide, The therapeutic efficacy of Piretanide can be decreased when used in combination with Naltrexone.]
[A08AA03, diethylpropion, Diethylpropion may increase the analgesic activities of Naltrexone.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Naltrexone.]
[N02CA01, dihydroergotamine, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Naltrexone.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Naltrexone.]
[J05AE08, atazanavir, The metabolism of Naltrexone can be decreased when combined with Atazanavir.]
[M03BX03, pridinol, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Pridinol.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Naltrexone.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Naltrexone.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Naltrexone is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of serotonin syndrome can be increased when Cisapride is combined with Naltrexone.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Naltrexone.]
[N05AX08, risperidone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Risperidone.]
[C03XA01, tolvaptan, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Naltrexone.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Salmeterol.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Naltrexone.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Naltrexone.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Naltrexone.]
[R06AA09, doxylamine, The risk or severity of adverse effects can be increased when Doxylamine is combined with Naltrexone.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Sertraline.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Sibutramine.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Naltrexone.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Naltrexone.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Naltrexone.]
[N02CC01, sumatriptan, The risk or severity of serotonin syndrome can be increased when Sumatriptan is combined with Naltrexone.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Terbinafine.]
[M03BX07, tetrazepam, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Thiocolchicoside.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Naltrexone.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Naltrexone.]
[N06AG03, toloxatone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Toloxatone.]
[C03CA04, torsemide, The therapeutic efficacy of Torasemide can be decreased when used in combination with Naltrexone.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Naltrexone is combined with Loprazolam.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Naltrexone.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Naltrexone.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Venlafaxine.]
[N03AX15, zonisamide, The therapeutic efficacy of Zonisamide can be decreased when used in combination with Naltrexone.]
[N05AX11, zotepine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Zotepine.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Naltrexone.]
[G02AB03, ergonovine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of serotonin syndrome can be increased when Ergotamine is combined with Naltrexone.]
[N03AG01, valproic acid, The metabolism of Naltrexone can be decreased when combined with Valproic acid.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Estazolam.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Fluvastatin.]
[C01CA15, gepefrine, Gepefrine may increase the analgesic activities of Naltrexone.]
[L02AA03, ethinyl estradiol, The metabolism of Naltrexone can be increased when combined with Ethinylestradiol.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Naltrexone.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Naltrexone is combined with Ethylmorphine.]
[N05AE03, sertindole, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Sertindole.]
[L04AD02, tacrolimus, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Tacrolimus.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Naltrexone.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Naltrexone.]
[N06AB08, fluvoxamine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fluvoxamine.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Naltrexone.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Naltrexone.]
[M01CB01, gold sodium thiomalate, The metabolism of Naltrexone can be decreased when combined with Sodium aurothiomalate.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fenfluramine.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Naltrexone.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Naltrexone is combined with Fentanyl.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Naltrexone.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Naltrexone.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Melitracen.]
[V03AZ01, ethanol, The risk or severity of adverse effects can be increased when Ethanol is combined with Naltrexone.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of hypotension and CNS depression can be increased when Fluphenazine is combined with Naltrexone.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Flurazepam.]
[S01BC04, flurbiprofen, The metabolism of Naltrexone can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fluspirilene.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Naltrexone.]
[G01AX06, furazolidone, The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Naltrexone.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Naltrexone.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Naltrexone.]
[N05CF04, eszopiclone, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Eszopiclone.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Naltrexone.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Ganciclovir.]
[N06AX08, bifemelane, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Bifemelane.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Gemfibrozil.]
[N04BC06, cabergoline, The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Naltrexone.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Naltrexone is combined with Alfentanil.]
[A06AH02, alvimopan, The risk or severity of adverse effects can be increased when Naltrexone is combined with Alvimopan.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Naltrexone.]
[L01EX02, sorafenib, The metabolism of Naltrexone can be decreased when combined with Sorafenib.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Naltrexone.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Naltrexone.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Naltrexone.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Naltrexone.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naltrexone.]
[R05DA03, hydrocodone, The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Naltrexone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naltrexone.]
[A12BA02, potassium citrate, The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Naltrexone.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Naltrexone.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Risedronic acid.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Naltrexone.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Naltrexone is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Naltrexone.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Paclitaxel.]
[M03BX02, tizanidine, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Tizanidine.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Naltrexone.]
[S01BC01, indomethacin, The metabolism of Naltrexone can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Naltrexone.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Alprazolam.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Naltrexone.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Naltrexone.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinethazone can be decreased when used in combination with Naltrexone.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Naltrexone.]
[N06AA13, iprindole, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of hypotension and CNS depression can be increased when Chlorproethazine is combined with Naltrexone.]
[N06AF01, isocarboxazid, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Isocarboxazid.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Naltrexone.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Isoniazid.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Naltrexone.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Naltrexone.]
[C02KD01, ketanserin, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Naltrexone can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Naltrexone.]
[V03AC03, deferasirox, The metabolism of Naltrexone can be decreased when combined with Deferasirox.]
[N04BC09, rotigotine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Rotigotine.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Naltrexone.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Naltrexone.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Naltrexone.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naltrexone.]
[N04BA01, levodopa, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Levodopa.]
[C03DB01, amiloride, The therapeutic efficacy of Amiloride can be decreased when used in combination with Naltrexone.]
[N02CA07, lisuride, The risk or severity of serotonin syndrome can be increased when Lisuride is combined with Naltrexone.]
[N06AA07, lofepramine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Lorazepam.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Naltrexone.]
[N05AH01, loxapine, The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Naltrexone.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Naltrexone.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Naltrexone.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Naltrexone.]
[L01EA03, nilotinib, The metabolism of Naltrexone can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Naltrexone.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Naltrexone.]
[A08AA05, mazindol, The risk or severity of serotonin syndrome can be increased when Mazindol is combined with Naltrexone.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Naltrexone.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Naltrexone.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Medazepam.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Naltrexone.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Naltrexone.]
[C03BA05, mefruside, The therapeutic efficacy of Mefruside can be decreased when used in combination with Naltrexone.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Naltrexone.]
[C01CA11, mephentermine, Mephentermine may increase the analgesic activities of Naltrexone.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Naltrexone.]
[N05BC01, meprobamate, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Naltrexone is combined with Meptazinol.]
[C03BC01, mersalyl, The therapeutic efficacy of Mersalyl can be decreased when used in combination with Naltrexone.]
[N05AC03, mesoridazine, The risk or severity of hypotension and CNS depression can be increased when Mesoridazine is combined with Naltrexone.]
[N05AX13, paliperidone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Naltrexone.]
[N06BA03, methamphetamine, Metamfetamine may increase the analgesic activities of Naltrexone.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Naltrexone.]
[N05CM01, methaqualone, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Methaqualone.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Lamivudine.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Naltrexone.]
[S01EC05, methazolamide, The therapeutic efficacy of Methazolamide can be decreased when used in combination with Naltrexone.]
[M03BA03, methocarbamol, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Methocarbamol.]
[L04AX03, methotrexate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methotrexate is combined with Naltrexone.]
[N05AA02, methotrimeprazine, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Naltrexone.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Naltrexone.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Naltrexone.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Methyldopa.]
[V04CG05, methylene blue, Naltrexone may increase the serotonergic activities of Methylene blue.]
[A03FA01, metoclopramide, The therapeutic efficacy of Naltrexone can be increased when used in combination with Metoclopramide.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be decreased when used in combination with Naltrexone.]
[N06AX03, mianserin, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Mianserin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Midazolam.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Naltrexone.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Minocycline.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may increase the analgesic activities of Naltrexone.]
[C01BD01, amiodarone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Naltrexone.]
[A04AA05, palonosetron, The risk or severity of serotonin syndrome can be increased when Palonosetron is combined with Naltrexone.]
[B02BX05, eltrombopag, The metabolism of Naltrexone can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Naltrexone can be decreased when combined with Pazopanib.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Naltrexone.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Naltrexone.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Raltegravir.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Naltrexone.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Naltrexone.]
[N02AF02, nalbuphine, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Naloxone.]
[S01GA01, naphazoline, Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Naltrexone.]
[N06BA01, amphetamine, Amphetamine may increase the analgesic activities of Naltrexone.]
[N06AX21, duloxetine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Duloxetine.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Naltrexone is combined with Remifentanil.]
[N05AX14, iloperidone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Naltrexone.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Desvenlafaxine.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Naltrexone.]
[N06AF02, nialamide, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Nialamide.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Naltrexone.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Nitrazepam.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Norfloxacin.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Nortriptyline is combined with Naltrexone.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Ofloxacin.]
[N06AA05, opipramol, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Naltrexone is combined with Opium.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Oxazepam.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Naltrexone is combined with Oxymorphone.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Naltrexone.]
[N05AH05, asenapine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Asenapine.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Naltrexone is combined with Tapentadol.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Naltrexone.]
[C02KC01, pargyline, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Pargyline.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Naltrexone.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Penicillamine.]
[N02AD01, pentazocine, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Naltrexone.]
[N05AB10, perazine, The risk or severity of hypotension and CNS depression can be increased when Perazine is combined with Naltrexone.]
[N04BC02, pergolide, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Naltrexone.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Naltrexone is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Phenelzine.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Naltrexone.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Naltrexone.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Naltrexone is combined with Phenoperidine.]
[A08AA01, phentermine, Phentermine may increase the analgesic activities of Naltrexone.]
[N03AB02, phenytoin, The metabolism of Naltrexone can be increased when combined with Phenytoin.]
[N07BB03, acamprosate, The bioavailability of Acamprosate can be increased when combined with Naltrexone.]
[C07AA03, pindolol, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Pindolol.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Atorvastatin.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Naltrexone.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Naltrexone.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Naltrexone is combined with Piritramide.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Naltrexone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Naltrexone.]
[C03AA05, polythiazide, The therapeutic efficacy of Polythiazide can be decreased when used in combination with Naltrexone.]
[J05AE03, ritonavir, The metabolism of Naltrexone can be increased when combined with Ritonavir.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Pitavastatin.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Naltrexone is combined with Prazepam.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Naltrexone.]
[M04AB01, probenecid, The metabolism of Naltrexone can be decreased when combined with Probenecid.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Naltrexone.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Naltrexone.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Naltrexone.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Naltrexone.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Naltrexone.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Naltrexone.]
[N05AC01, periciazine, The risk or severity of hypotension and CNS depression can be increased when Periciazine is combined with Naltrexone.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Naltrexone.]
[N01AX10, propofol, Naltrexone may increase the sedative activities of Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Naltrexone.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Naltrexone.]
[N02CC04, rizatriptan, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Rizatriptan.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Naltrexone.]
[N06AA11, protriptyline, The risk or severity of serotonin syndrome can be increased when Protriptyline is combined with Naltrexone.]
[R01BA02, pseudoephedrine, Pseudoephedrine may increase the analgesic activities of Naltrexone.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Naltrexone.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Naltrexone.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Naltrexone.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Naltrexone.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Naltrexone.]
[M03BA04, styramate, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Styramate.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Naltrexone.]
[P01BC01, quinine, The risk or severity of respiratory depression can be increased when Naltrexone is combined with Quinine.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Ranitidine.]
[J04AB02, rifampin, The metabolism of Naltrexone can be increased when combined with Rifampicin.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Naltrexone.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Naltrexone.]
[N04BD01, selegiline, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Selegiline.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Naltrexone.]
[C03DA01, spironolactone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Naltrexone.]
